IRIS
BIANCO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.903
NA - Nord America 6.649
EU - Europa 5.994
SA - Sud America 832
AF - Africa 210
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 7
Totale 21.610
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.383
SG - Singapore 3.417
RU - Federazione Russa 2.516
VN - Vietnam 1.594
CN - Cina 1.527
IT - Italia 1.515
BR - Brasile 672
HK - Hong Kong 563
DE - Germania 426
FR - Francia 289
UA - Ucraina 239
FI - Finlandia 230
NL - Olanda 227
CA - Canada 179
IN - India 169
GB - Regno Unito 146
IE - Irlanda 144
JP - Giappone 125
CI - Costa d'Avorio 79
SE - Svezia 78
BD - Bangladesh 77
KR - Corea 71
AR - Argentina 70
MX - Messico 50
ZA - Sudafrica 49
PK - Pakistan 48
PL - Polonia 48
PH - Filippine 46
TH - Thailandia 36
IQ - Iraq 35
ES - Italia 30
ID - Indonesia 27
TR - Turchia 24
EC - Ecuador 23
BE - Belgio 20
UZ - Uzbekistan 20
EG - Egitto 19
VE - Venezuela 18
AT - Austria 15
MA - Marocco 15
MY - Malesia 15
CO - Colombia 12
LT - Lituania 12
PY - Paraguay 12
SA - Arabia Saudita 12
TW - Taiwan 12
TN - Tunisia 11
IL - Israele 10
AU - Australia 9
CL - Cile 9
JM - Giamaica 8
JO - Giordania 8
NP - Nepal 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
ET - Etiopia 7
IR - Iran 7
AZ - Azerbaigian 6
BG - Bulgaria 6
DZ - Algeria 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
CZ - Repubblica Ceca 5
GR - Grecia 5
HN - Honduras 5
KE - Kenya 5
LB - Libano 5
TT - Trinidad e Tobago 5
BO - Bolivia 4
KH - Cambogia 4
KZ - Kazakistan 4
PT - Portogallo 4
SI - Slovenia 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
BS - Bahamas 3
CH - Svizzera 3
CY - Cipro 3
DK - Danimarca 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
OM - Oman 3
RO - Romania 3
SV - El Salvador 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
CG - Congo 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MK - Macedonia 2
MN - Mongolia 2
NI - Nicaragua 2
PA - Panama 2
QA - Qatar 2
Totale 21.572
Salva come PNG Salva come JPEG
Città #
Singapore 1.652
San Jose 1.042
Moscow 641
Ashburn 551
Hong Kong 542
Chandler 524
Beijing 478
Ho Chi Minh City 455
Naples 371
Hanoi 356
Hefei 311
Santa Clara 245
Jacksonville 237
The Dalles 208
Dallas 194
Amsterdam 190
Napoli 189
Los Angeles 170
Lauterbourg 167
Munich 160
Millbury 156
New York 127
Princeton 116
Tokyo 104
Boston 87
Buffalo 86
São Paulo 77
Nanjing 75
Haiphong 71
Da Nang 64
Redondo Beach 64
Rome 62
Turku 61
Wilmington 61
Ottawa 56
Woodbridge 54
Seoul 52
Orem 49
Houston 47
Des Moines 46
Council Bluffs 45
Kochi 45
Frankfurt am Main 42
Montreal 42
Helsinki 40
Seattle 38
Toronto 38
London 37
Milan 37
Chicago 36
Brooklyn 35
Nanchang 35
Warsaw 35
Biên Hòa 30
Dong Ket 28
Pune 28
Stockholm 28
Denver 27
Mexico City 27
Falkenstein 26
Hebei 25
Hải Dương 25
Caserta 24
Nuremberg 24
Boardman 23
Hicksville 23
Shenyang 23
Atlanta 21
Johannesburg 21
Phoenix 21
Chennai 20
Lawrence 20
Tianjin 20
Changsha 19
Norwalk 19
Ann Arbor 18
Tashkent 18
Can Tho 17
Rio de Janeiro 17
Belo Horizonte 16
Baghdad 15
Islamabad 15
Jiaxing 15
Lahore 15
Ninh Bình 15
Quận Ba 15
Salt Lake City 15
Shanghai 15
Brussels 14
Kronberg 14
Porto Alegre 14
Redwood City 14
San Francisco 14
Guangzhou 13
Dublin 12
Formia 12
Manchester 12
Poplar 12
San Mateo 12
Charlotte 11
Totale 11.585
Salva come PNG Salva come JPEG
Nome #
null 223
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 213
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 198
Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents 197
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 188
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 174
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 165
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 163
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 162
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 161
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 160
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 160
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 159
NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine 158
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 154
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 153
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 152
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 152
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 152
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 151
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 150
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 150
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 149
Prevention of cardiovascular complications in elderly cancer patients 149
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 148
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 148
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 147
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 146
Studio dei meccanismi autocrini e paracrini di attivazione di Hedgehog in modelli tumorali umani. 146
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 145
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 145
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 144
Mechanisms of resistance to mTOR inhibitors 144
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 142
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 142
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 142
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 142
AXL is an oncotarget in human colorectal cancer 141
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 140
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 140
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 140
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 140
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 140
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 139
Mechanisms of lapatinib resistance in HER2-driven breast cancer 139
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 137
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 137
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 136
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 136
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 134
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 133
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 133
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 132
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 132
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 131
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 130
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 130
Approaches for targeting cancer stem cells drug resistance 130
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 129
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 129
Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study 129
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 129
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 129
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 129
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 129
RET Inhibitors in Non-Small-Cell Lung Cancer 128
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 128
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 128
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 126
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study 126
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 126
Preliminary analysis of chemotheraphy-induced cardiotoxicity in breast cancer patients trated with Amifostine. 125
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 124
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 124
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 124
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 124
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 123
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 123
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 122
From biology to therapy: Improvements of therapeutic options in Lung cancer 122
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 121
Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe 121
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 120
Core curriculum. Oncologia clinica 120
COMBINED TARGETING OF EGFR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER. 119
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 119
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 117
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 115
Combination of biological therapies in non-small cell lung cancer. 115
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. 115
The mechanisms of resistance to EGFR inhibitors. 115
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 115
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 115
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials 115
Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications 115
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 114
KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer 113
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 112
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 112
A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. 111
Totale 13.819
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.493
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.493
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202144 0 0 0 0 0 0 0 0 0 0 0 44
2021/2022879 16 1 11 25 12 25 11 29 156 73 206 314
2022/20231.367 152 110 48 102 146 163 8 129 207 197 64 41
2023/20241.000 35 140 138 100 45 106 25 118 20 21 194 58
2024/20255.494 236 258 15 99 165 279 575 372 336 600 2.117 442
2025/202610.967 1.179 794 1.238 976 1.837 498 1.280 573 1.381 736 365 110
Totale 21.923